ZL006-05 是一种口服有效、可通过血脑屏障的 nNOS–PSD-95 和 α2-containing GABAA 双靶点抑制剂,可阻断 nNOS-PSD-95 蛋白相互作用并选择性增强 α2-containing GABAA 受体功能,从而降低中枢敏化并增强 GABA 能抑制性神经传递,可用于神经病理性疼痛、癌痛、化疗诱导的外周神经病理性疼痛、缺血性卒中、卒中后抑郁和焦虑研究。
产品编号: MS-K30979 CAS No.: 2486316-20-3 分子式: C24H27Cl2NO4 分子量: 464.38
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

ZL006-05 是一种口服有效、可通过血脑屏障的 nNOS–PSD-95 和 α2-containing GABAA 双靶点抑制剂,可阻断 nNOS-PSD-95 蛋白相互作用并选择性增强 α2-containing GABAA 受体功能,从而降低中枢敏化并增强 GABA 能抑制性神经传递,可用于神经病理性疼痛、癌痛、化疗诱导的外周神经病理性疼痛、缺血性卒中、卒中后抑郁和焦虑研究。

生物实验数据

生物活性 ZL006-05 is an orally effective, blood-brain barrier-penetrant dual-target inhibitor of nNOS–PSD-95 and α2-containing GABAA that blocks the nNOS-PSD-95 protein interaction and selectively enhances α2-containing GABAA receptor function, thereby reducing central sensitization and enhancing GABAergic inhibitory neurotransmission, and can be used for research on neuropathic pain, cancer pain, chemotherapy-induced peripheral neuropathic pain, ischemic stroke, post-stroke depression, and anxiety.
IC50 & Target

nNOS

 

GABAA receptor

 

PSD-95

 

体外研究
(In Vitro)

ZL006-05 (0-100 μM) 增强脊髓背角 lamina II 神经元中 GABA 诱导电流;1、10 和 100 μM 分别使 GABA 诱导电流振幅增加 1.42 倍、1.71 倍和 1.68 倍。
ZL006-05 (10 μM) 使 lamina II 神经元中 Isoguvacine hydrochloride (MS-J56183) 诱导的 GABAA receptor 电流增加 1.57 倍,并通过将 Isoguvacine 的 EC50 从 38.22 μM 降至 5.12 μM,使其浓度-反应曲线左移。
ZL006-05 (10 μM) 使前扣带皮层神经元中 Isoguvacine 诱导电流增加 1.53 倍。
ZL006-05 (0.1 nM-10 μM; 与 GABA 共灌) 选择性增强表达 α2β3γ2 GABAA receptor 的 HEK293 细胞中 GABA 诱导电流,而对 α1β2γ2 GABAA receptor 未显示明显增强作用。

体内研究
(In Vivo)

ZL006-05 (4 mg/kg; 静脉注射; RM-1 接种后每日 1 次,连续 6 天) 在 RM-1 诱导的转移性骨癌痛小鼠模型中消除 RM-1 诱导的机械性痛觉异常、热痛觉过敏、冷痛觉过敏和自发性疼痛行为,抑制 RM-1 诱导的同侧 L3/L4 脊髓背角神经元和星形胶质细胞过度活化。
ZL006-05 (0.4-4 mg/kg; 静脉注射; 每日 1 次; 从 RM-1 接种后第 7 天开始连续 8 天) 在骨癌痛维持期剂量依赖性降低 RM-1 诱导的机械性痛觉异常、热痛觉过敏、冷痛觉过敏和自发性疼痛行为。
ZL006-05 (10 mg/kg; 静脉注射; 每日 1 次; 从首次 Paclitaxel (HY-B0015) 注射后第 9 天开始连续 7 天) 在化疗诱导的外周神经病理性疼痛小鼠模型中降低 Paclitaxel (HY-B0015) 诱导的双侧机械性痛觉异常、热痛觉过敏和冷痛觉过敏,降低 Paclitaxel (HY-B0015) 诱导的腰段脊髓背角 p-ERK1/2 和 GFAP 上调。
ZL006-05 (60 mg/kg/day; 灌胃; 连续 11 天) 在大脊神经结扎 (Spinal Nerve Ligation, SNL) 神经病理性疼痛模型中降低机械性痛觉过敏,且不产生镇痛耐受。
ZL006-05 (60 mg/kg/day; 灌胃; 连续 28 天) 在 SNL 诱导的神经病理性疼痛小鼠中维持长期抗伤害作用,而 pregabalin 在相同给药周期下出现严重镇痛耐受。
ZL006-05 (0.3 mg/d; 渗透泵鞘内输注; 连续 11 天) 经鞘内持续给药后增加脊髓背角 lamina I 兴奋性神经元的 mIPSC 振幅,而不影响 mEPSCs。
ZL006-05 (0.5-4 mg/kg; 静脉注射; 再灌注后 60 min 给药) 在雌雄大鼠 tMCAO 模型中剂量依赖性降低 48 h 后的脑梗死体积和神经功能评分,有效剂量为 1 mg/kg。
ZL006-05 (2 mg/kg; 静脉注射; 再灌注后 60 min 给药) 在雄性大鼠 tMCAO 模型中降低第 7 天的脑梗死体积、足误步次数和神经功能缺损评分。
ZL006-05 (2 mg/kg; 静脉注射; 缺血后 2 h, 26 h 给药) 在小鼠光血栓性卒中模型中改善第 7 天运动功能并降低脑梗死体积。
ZL006-05 (2 mg/kg; 静脉注射; 缺血后 6 或 12 h 首次给药,首次给药后 24 h 给予第二次剂量) 在大鼠光血栓性中风模型中改善造模第 7 天感觉运动功能并降低脑梗死体积。
ZL006-05 (2 mg/kg/day; 静脉注射; 缺血后连续给药 3 或 7 天) 在大鼠光血栓卒中或 tMCAO 模型中改善长期神经功能缺损、感觉运动功能和空间学习能力。
ZL006-05 (2 mg/kg; 静脉注射; 再灌注 60 min 给药) 降低缺血性卒中后 tPA 诱导的出血性转化和脑损伤恶化。
ZL006-05 (2 mg/kg; 静脉注射; 给药后 60 min 进行行为学检测) 在小鼠中产生快速起效的抗焦虑样和抗抑郁样作用。
ZL006-05 (1, 2 mg/kg; 静脉注射; 28 天 UCMS 暴露后单次给药) 在给药后 60 min 逆转 UCMS 诱导的焦虑相关和抑郁相关行为,其中 2 mg/kg 作用显著。
ZL006-05 (2 mg/kg/day; 静脉注射; 卒中后连续 7 天) 在小鼠中防止 tMCAO 诱导的焦虑相关和抑郁相关行为改变。
ZL006-05 (2 mg/kg; 静脉注射; 短暂大脑中动脉阻塞再灌注后 60 min 单次给药) 降低小鼠卒中诱导的梗死周围皮层 nNOS-PSD-95 interaction,并增加微型抑制性突触后电流振幅,提示其增强抑制性突触传递。
ZL006-05 (10-40 mg/kg; 单次给药或 28 天重复静脉给药) 大鼠全身暴露参数 Cmax、AUC 呈剂量依赖性升高,无性别差异,未观察到药物蓄积现象且显示出较高安全性。

Animal Model: RM-1-induced metastatic bone cancer pain 8-week-old male C57BL/6 mice model
Dosage: 4 mg/kg
Administration: Intravenous injection (i.v.); 30 min after RM-1 inoculation and then once daily for 6 days
Result: Abolished RM-1-induced mechanical allodynia, heat hyperalgesia and cold hyperalgesia on the ipsilateral side.
Reduced spontaneous pain behaviors, including guarding duration and flinching number.
Showed stronger antinociceptive activity than ZL005 or ZL006 at the same dose.
Did not alter basal paw withdrawal responses or locomotor function.
Animal Model: RM-1-induced metastatic bone cancer pain 8-week-old male C57BL/6 mice model maintenance phase
Dosage: 0.4, 2, 4 mg/kg
Administration: Intravenous injection (i.v.); once daily; for 8 consecutive days starting on day 7 after RM-1 inoculation
Result: Reduced RM-1-induced mechanical allodynia, heat hyperalgesia, cold hyperalgesia and spontaneous pain in a dose-dependent manner.
At 4 mg/kg on day 14, reduced paw withdrawal frequencies to 0.07 g and 0.4 g von Frey filaments by 62% and 50%, respectively.
At 4 mg/kg on day 14, increased paw withdrawal latencies to heat and cold stimuli by 1.58-fold and 1.39-fold, respectively.
At 4 mg/kg on day 14, reduced guarding duration and flinching number by 78% and 86%, respectively.
Did not alter basal responses on the contralateral hind paw.
Animal Model: 8-week-old male C57BL/6 mice RM-1-induced dorsal horn neuronal and astrocyte hyperactivity model
Dosage: 4 mg/kg
Administration: Intravenous injection (i.v.); 30 min before RM-1 inoculation and then once daily for 6 consecutive days
Result: Prevented RM-1-induced p-ERK1/2 upregulation in the ipsilateral L3/L4 dorsal horn, indicating suppression of neuronal hyperactivity.
Prevented RM-1-induced GFAP upregulation in the ipsilateral L3/L4 dorsal horn, indicating suppression of astrocyte hyperactivity.
Did not alter basal p-ERK1/2, total ERK1/2 or GFAP expression in HBSS-inoculated mice.
Animal Model: 8-week-old male CD1 mice paclitaxel-induced peripheral neuropathic pain mouse model
Dosage: 10 mg/kg
Administration: Intravenous injection (i.v.); once daily; for 7 consecutive days starting on day 9 after the first paclitaxel injection
Result: Reduced paclitaxel-induced bilateral mechanical allodynia, heat hyperalgesia and cold hyperalgesia on days 11, 13 and 15 after the first paclitaxel injection.
Did not alter basal responses to mechanical, heat or cold stimuli in vehicle-treated mice.
Maintained normal locomotor function.
Animal Model: 8-week-old male CD1 mice paclitaxel-induced dorsal horn neuronal and astrocyte hyperactivity model
Dosage: 10 mg/kg
Administration: Intravenous injection (i.v.); once daily; for 7 consecutive days starting on day 9 after the first paclitaxel injection
Result: Prevented paclitaxel-induced p-ERK1/2 and GFAP upregulation in the lumbar enlargement dorsal horn on day 15 after the first paclitaxel injection.
Attenuated paclitaxel-induced increases in membrane nNOS level and PSD-95-nNOS binding density in the lumbar dorsal horn.
Did not significantly change basal PSD-95 level or total nNOS and PSD-95 levels.
Animal Model: 8-week-old male SD rat SNL-induced neuropathic pain rat model
Dosage: 60 mg/kg/day
Administration: Intragastric administration (i.g.); once daily; for 11 days
Result: Reduced SNL-induced mechanical hyperalgesia and thermal pain.
Maintained antinociceptive activity during repeated dosing.
Did not produce analgesic tolerance during the 11-day administration period.
Animal Model: 8-week-old male SD rat SNL-induced neuropathic pain mouse model
Dosage: 60 mg/kg/day
Administration: Intragastric administration (i.g.); once daily; for 28 days
Result: Maintained long-term antinociceptive activity during 28 days of repeated dosing.
Produced sustained relief of SNL-induced neuropathic pain without analgesic tolerance.
Showed a better long-term tolerance profile than pregabalin, which produced severe analgesic tolerance under the same 28-day treatment duration.
Animal Model: Adult SD rat tMCAO model
Dosage: 0.5, 1, 2, 4 mg/kg
Administration: Intravenous injection (i.v.); single administration at 60 min after reperfusion
Result: Reduced infarct volume and neurological score dose-dependently at 48 h after tMCAO in male and female rats.
Showed an effective dose of 1 mg/kg.
At 2 mg/kg, showed effects comparable with edaravone dexborneol (ED).
Animal Model: Adult SD rat tMCAO long-term functional recovery model
Dosage: 2 mg/kg/day
Administration: Intravenous injection (i.v.); once daily; for 3 or 7 consecutive days after cerebral ischemia
Result: Reduced modified Neurological Severity Score (mNSS) and foot faults on day 28 after tMCAO.
Improved spatial learning in Morris water maze during days 30-35 after stroke.
Improved long-term neurological deficit, motor function and spatial learning without changing swimming speed.
Animal Model: 8-week-old C57BL/6 mice photothrombotic stroke model
Dosage: 2 mg/kg
Administration: Intravenous injection (i.v.); two doses at 2 and 26 h after ischemia
Result: Reduced contralateral forelimb foot faults in the grid-walking test.
Reduced asymmetry index in the cylinder test.
Reduced infarct volume on day 7 after ischemia.
Improved motor function and reduced permanent ischemic injury.
Animal Model: Adult SD rat photothrombotic permanent stroke delayed treatment model
Dosage: 2 mg/kg
Administration: Intravenous injection (i.v.); first dose at 6 or 12 h after ischemia and second dose 24 h after the first dose
Result: Improved motor function in the grid-walking test on day 7 after ischemia.
Improved somatosensory function in the modified sticky-tape test on day 7 after ischemia.
Reduced infarct volume measured by Nissl staining.
Showed a therapeutic time window of up to 12 h after permanent ischemia.
Animal Model: 8-week-old C57BL/6 mice UCMS-induced anxiety and depression model
Dosage: 1, 2 mg/kg
Administration: Intravenous injection (i.v.); single administration during 2-12 h after the end of 28-day UCMS exposure
Result: At 2 mg/kg, reversed UCMS-induced behavioral modifications at 60 min after injection.
Increased time spent in open arms in the EPM test.
Decreased latency to feed in the NSF test.
Reduced immobility time in the FST and TST.
Increased sucrose water preference in the SPT.
Did not affect locomotor activity or food consumption.
Animal Model: 8-week-old C57BL/6 mice tMCAO-induced anxiety and depression model
Dosage: 2 mg/kg/day
Administration: Intravenous injection (i.v.); once daily; for 7 consecutive days after stroke
Result: Prevented tMCAO-induced behavioral modifications.
Increased sucrose water preference in the SPT on day 7 after stroke.
Decreased latency to feed in the NSF test on day 10 after stroke.
Did not affect food consumption.

化学信息

分子量 464.38
分子式 C24H27Cl2NO4
CAS No. 2486316-20-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础